Hepatorenal Syndrome Clinical Trial
Official title:
A Multi-Center, Open Label, Collaborative Research Study to Treat HRS-AKI Patients With Continuous Terlipressin Infusion
Hepatorenal syndrome-acute kidney injury (HRS-AKI), a potentially reversible renal failure, is a serious, rapidly progressing, often fatal, complication of decompensated cirrhosis. Terlipressin is a synthetic vasopressin analogue that acts as a systemic vasoconstrictor via the vascular vasopressin V1 receptors. In HRS-AKI patients the strong V1 receptor-mediated vasoconstrictor activity of terlipressin, particularly in the splanchnic area, increases effective intravascular volume and mean arterial pressure (MAP), ameliorates renin-angiotensin-aldosterone system and sympathetic nervous system hyperactivity, and improves renal blood flow. The INFUSE trial will evaluate the use of continuous terlipressin infusion in patients on the liver transplant waiting list with HRS-AKI.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00370253 -
Noradrenalin vs Terlipressin in Hepatorenal Syndrome
|
Phase 3 | |
| Completed |
NCT00359853 -
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
|
Phase 4 | |
| Completed |
NCT01436500 -
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
|
Phase 2 | |
| Completed |
NCT01143246 -
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
|
Phase 3 | |
| Recruiting |
NCT05346393 -
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
|
N/A | |
| Terminated |
NCT00742339 -
Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
|
Phase 2/Phase 3 | |
| Terminated |
NCT00734136 -
Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome
|
N/A | |
| Recruiting |
NCT06095440 -
A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
|
||
| Completed |
NCT02097784 -
Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury
|
N/A | |
| Recruiting |
NCT04898010 -
The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I
|
N/A | |
| Recruiting |
NCT05875948 -
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
|
Phase 2 | |
| Completed |
NCT04416282 -
Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.
|
N/A | |
| Recruiting |
NCT02049125 -
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
|
N/A | |
| Completed |
NCT00764049 -
Single Pass Albumin Dialysis in Patients With Cirrhosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00089570 -
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
|
Phase 3 | |
| Withdrawn |
NCT01587222 -
Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure
|
Phase 2 | |
| Recruiting |
NCT02489864 -
The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure
|
Phase 4 | |
| Recruiting |
NCT02434445 -
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
|
N/A | |
| Completed |
NCT02770716 -
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
|
Phase 3 | |
| Completed |
NCT05387811 -
International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
|